T2 asthma and T2-associated diseases: a consolidated approach to biological therapy

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


This article is dedicated to the main characteristics of severe bronchial asthma (SBA) and its heterogeneity. In particular, it describes T2 asthma and the role of the main cytokines involved in T2 inflammation. It focuses on the role of IL-4 and IL-13 in the pathogenesis of asthma and other T2-associated diseases, as key cytokines in the initiation and maintenance of T2 inflammation. The article presents the results of experimental studies proving that the activation of IL-4/IL-13 can cause significant hyperresponsiveness of the human airway smooth muscles and the combined blockade of the activity of these cytokines using a human monoclonal antibody against the common IL-4/13 receptor á-subunit-dupilumab-determines the clinical efficacy not only in relation to exacerbations and control of asthma symptoms, but also an improvement of the lung function and a reduction in bronchial hyperresponsiveness. When type 2 helper cells (Th2) interact with antigen-presenting cells, IL-4 and IL-13 are simultaneously released, therefore, blocking IL-4Rá is more effective than blocking each of the ligands separately, which explains the high efficacy of dupilumab not only in T2 asthma, but also other T2-associated diseases: atopic dermatitis and chronic rhinosinusitis with nasal polyps. In addition to asthma and atopic dermatitis, a new indication for dupilumab, chronic rhinosinusitis with nasal polyps, has recently been approved.

According to the recommendations of the European Academy of Allergy and Clinical Immunology (EAACI) for the biological therapy of SBA 2020, dupilumab is recommended as an add-on maintenance therapy in adults and children aged 12–17 years old with uncontrolled severe T2 asthma, including asthma with the allergic and eosinophilic phenotype, as well as mixed (when there are signs of both phenotypes) and steroid-dependent asthma. At the same time, dupilumab is well tolerated.


Restricted Access

Natalya M. Nenasheva

Federal State Budgetary Educational Institution of Additional Professional Education Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: 1444031@gmail.com
ORCID iD: 0000-0002-3162-2510

Russian Federation, Moscow

Head of Allergology and Immunology Department of Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation, PhD, professor

  1. Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Invest. 2019;129(4):1493–503. doi: 10.1172/JCI124611
  2. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372(9643):1107–1119. doi: 10.1016/S0140-6736(08)61452-X
  3. Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355–360. doi: 10.1016/j.jaci.2010.11.037
  4. Agache I, Akdis C, Jutel M, Virchow JC. Untangling asthma phenotypes and endotypes. Allergy. 2012;67(7):835–846. doi: 10.1111/j.1398-9995.2012.02832.x
  5. Agache IO. From phenotypes to endotypes to asthma treatment. Curr Opin Allergy Clin Immunol. 2013;13(3):249–256. doi: 10.1097/ACI.0b013e32836093dd
  6. Agache I, Akdis CA. Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine. Allergol Int. 2016;65(3):243–252. doi: 10.1016/j.alit.2016.04.011
  7. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(8):796. Corrected and republished from: Am J Respir Crit Care Med. 2009;180(5):388–395. doi: 10.1164/rccm.200903-0392OC
  8. Bhakta NR, Woodruff PG. Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunol Rev. 2011;242(1):220–232. doi: 10.1111/j.1600-065X.2011.01032.x
  9. Nenasheva NM. Т2-high and T2-low bronchial asthma, endotype characteristics and biomarkers. Pulmonologiya. 2019;29(2):216–228. (In Russ). doi: 10.18093/0869-0189-2019-29-2-216-228
  10. Agache I. Severe asthma phenotypes and endotypes. Semin Immunol. 2019;46:101301. doi: 10.1016/j.smim.2019.101301
  11. Agache I, Sugita K, Morita H, Akdis M, Akdis CA. The complex type 2 endotype in allergy and asthma: from laboratory to bedside. Curr Allergy Asthma Rep. 2015;15(6):29. doi: 10.1007/s11882-015-0529-x
  12. Agache I, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, et al. EAACI Biologicals Guidelines – Recommendations for severe asthma. Allergy. 2020:1–31. doi: 10.1111/all.14425
  13. Sergeeva GR, Emelyanov AV, Korovina OV, Znakhurenko AA, Leshenkova EV, Kozyreva LV, Asatiani N. Severe asthma: characteristics of patients in clinical practice. Terapevticheskii arkhiv. 2015;87(12):26–31 (In Russ.). doi: 10.17116/terarkh2015871226-31
  14. Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108(12):1723–1732. doi: 10.1016/j.rmed.2014.10.007
  15. Shau DE, Sousa AR, Fowler SJ, Fleming LJ, Robers G, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308–1321. doi: 10.1183/13993003.00779-201
  16. Gandhi NA, Pirozzi G, Graham NM. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi: 10.1080/1744666X.2017.1298443
  17. Weinstein SF, Katial R, Jayawardena S, Pirozzi G, Staudinger H, Eckert L, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018;142(1):171–177.e1. doi: 10.1016/j.jaci.2017.11.051
  18. Jonstam K, Swanson BN, Mannent LP, Cardell LO, Tian N, Wang Y, et al. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy. 2019;74(4):743–752. doi: 10.1111/all.13685
  19. Furue K, Ito T, Tsuji G, Ulzii D, Vu YH, Kido-Nakahara M, et al. The IL-13-OVOL1-FLG axis in atopic dermatitis. Immunology. 2019;158(4):281–286. doi: 10.1111/imm.13120
  20. Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:155–172. doi: 10.1016/j.jaci.2018.08.022
  21. Markowitz JE, Jobe L, Miller M, Frost C, Laney Z, Eke R. Safety and efficacy of reslizumab for children and adolescents with eosinophilic esophagitis treated for 9 years. J Pediatr Gastroenterol Nutr. 2018;66(6):893–897. doi: 10.1097/MPG.0000000000001840
  22. Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–122.e10. doi: 10.1053/j.gastro.2019.09.042
  23. Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21:425–456. doi: 10.1146/annurev.immunol.21.120601.141142
  24. Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep. 2013;13(5):415–420. doi: 10.1007/s11882-013-0373-9
  25. Paul WE. History of interleukin-4. Cytokine. 2015;75(1):3–7. doi: 10.1016/j.cyto.2015.01.038
  26. Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, et al. Interleukin-13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B-cells. Proc Natl Acad Sci U S A. 1993;90(8):3730–3734. doi: 10.1073/pnas.90.8.3730
  27. Gascan H, Gauchat JF, Roncarolo MG, Yssel H, Spits H, de Vries JE. Human B-cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T-cell clones. J Exp Med. 1991;173(3):747–750. doi: 10.1084/jem.173.3.747
  28. Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007;119(6):1303–1310. doi: 10.1016/j.jaci.2007.03.048
  29. Le Floc’h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204. doi: 10.1111/all.14151
  30. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi: 10.1056/NEJMoa1804092.
  31. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi: 10.1056/NEJMoa1804093
  32. Manson ML, Säfholm J, James A, Johnsson AK, Bergman P, Al-Ameri M, et al. IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways. J Allergy Clin Immunol. 2020;145(3):808–817.e2. doi: 10.1016/j.jaci.2019.10.037
  33. Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Vancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. doi: 10.1038/nrd4624
  34. Bourdin A, Fabry-Vendrand C, Ostinelli J, Ait-Yahia M, Darnal E, Bouee S, et al. The burden of severe asthma in France: a case-control study using a medical claims database. J Allergy Clin Immunol Pract. 2019;7(5):1477–1487. doi: 10.1016/j.jaip.2018.12.029
  35. Tiotiu A, Plavec D, Novakova S, Mihaicuta S, Novakova P, Labor M, et al. Current opinions for the management of asthma associated with ear, nose and throat comorbidities. Eur Respir Rev. 2018;27(150):180056. doi: 10.1183/16000617.0056-2018
  36. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;Suppl 29:1–464. doi: 10.4193/Rhin20.600
  37. Tay TR, Hew M. Comorbid “treatable traits” in difficult asthma: current evidence and clinical evaluation. Allergy. 2018;73:1369–1382. doi: 10.1111/all.13370
  38. Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012;67(1):91–98. doi: 10.1111/j.1398-9995.2011.02709.x
  39. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45–53. doi: 10.2147/JAA.S86251
  40. Nenasheva N, Belevsky A, Kravchenko O, Avdeev S, Emel’yanov A, Kurbacheva O, Leschenko I. Late Breaking Abstract – Preliminary analysis of the data of patients with severe bronchial asthma included in the Russian National Register of Severe Asthma (RSAR). Eur Respir J. 2019;54(Suppl 63):PA4261. doi: 10.1183/13993003.congress-2019.pa4261
  41. Maspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, et al. Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2020;8(2):527–539.e9. doi: 10.1016/j.jaip.2019.07.016
  42. Busse W, Maspero J, Katelaris C, Saralaya D, Guillonneau S, Zhang B, et al. Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in LIBERTY ASTHMA QUEST. Eur Respir J. 2018;52(Suppl 62):PA1125. doi: 10.1183/13993003.congress-2018.pa1125
  43. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis. JAMA. 2016;315(5):469–479. doi: 10.1001/jama.2015.19330
  44. Bachert C, Hellings PW, Mullol J, Naclerio RM, Chao J, Amin N, et al. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Pract. 2019;7(7):2447–2449. doi: 10.1016/j.jaip.2019.03.023
  45. Bachert C, Jan JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650. doi: 10.1016/S0140-6736(19)31881-1

Supplementary files

Supplementary Files Action
1. Fig. 1. IL-4 and IL-13 are the main and central type 2 cytokines that determine the pathophysiological mechanisms of the development of T2 inflammation (adapted from Gandhi NA et al., 2017 [16]) View (1MB) Indexing metadata
2. Fig. 2. Dual inhibition of IL-4/IL-13 prevents HDMA-induced impairment of the lung function (c – genetically modified mice were challenged with HDMA or saline for 4 weeks. Two groups of mice exposed to HDMA were subsequently injected with hIgGcontr or anti-IL-4Rα antibodies; d–f – 72–100 h after the last exposure to HDMA, pulmonary function and airway hyperresponsiveness in mice were assessed using negative pressure-driven forced expiratory maneuvers (NPFE) and the forced oscillation technique (FOT) on the FlexiVent platform. After registration of the baseline parameters (d), the mice received increasing doses of methacholine via a nebulizer, for 10 seconds each (0; 2; 4; 6; 10 and 14 mg/mL), after which the functional parameters were measured again (e, f). For each dose of methacholine, FEV0,1 is presented in absolute figures (e) and in relation to the baseline (f) (n≥5 mice in the group); d – * p<0.01 compared with mice that were not exposed to HDMA; e, f – # p<0.1; ## – p<0.01; ### – p<0.001 for mice not exposed to HDMA, compared to mice exposed to HDMA; * – p<0.01; ** – p<0.001 for anti-IL-4Rα antibodies compared to groups treated with IgG control (other significant comparisons not shown), adapted from [29] View (764KB) Indexing metadata
3. Fig. 3. Effect of dupilumab on BH stimulated by IL-13 and IL-4. Cumulative concentration-response curves were obtained for histamine in human bronchial rings treated for 2 days with IL-13 (a) and IL-4 (b) with and without dupilumab (1 μmol). Statistical comparison of the cytokine pEC50 in human bronchial rings treated with dupilumab and in bronchial segments treated with IL-13 and IL-4 was performed using the paired t-test; a – p<0.01; b – p<0.05. Maximum induction of intracellular calcium by histamine in human airway smooth muscles treated with IL-13 (c) or IL-4 (d) for 24 h with or without dupilumab. Data are presented as mean ± standard error of the mean [32] View (446KB) Indexing metadata
4. Fig. 4. The main mechanism of action of dupilumab (adapted from Gandhi NA et al., 2016 [33]; JAK1,2,3 – Janus kinases; TYK2 – tyrosine kinase; STAT – transcription factors) View (99KB) Indexing metadata
5. Fig. 5. Dupilumab significantly reduced the frequency of severe exacerbations in patients with uncontrolled persistent bronchial asthma (adapted from [30]) View (80KB) Indexing metadata
6. Fig. 6. The study of a steroid-sparing effect (VENTURE): a statistically significant decrease in the need for OCS compared to placebo at week 24 in the general population while using dupilumab (adapted from [31]) View (320KB) Indexing metadata
7. Fig. 7. A reduction in the frequency of exacerbations and improvement of the lung function (adapted from [34]) View (267KB) Indexing metadata

Views

Abstract - 33

PDF (Russian) - 1

PDF (English) - 1

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies